Otsuka Holdings: shift to higher-margin drugs could support earnings
Jefferies expects Otsuka Holdings' move toward higher-value assets to lift margins and EPS above consensus. The shares are up 1.1%.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
According to Market Talk, citing a note from Jefferies analysts, Otsuka Holdings' shift toward higher-value assets should improve margins and push earnings per share above market expectations in the coming years. The bank points to Voyxact, a drug that reduces protein in the urine of adults with kidney disease, and Zipalertinib, a potential lung-cancer treatment, as examples.
The analysts say a broader mix of higher-margin products across several franchises makes earnings more durable and less reliant on any single drug. Jefferies raised its target price on the stock to 14,500 yen from 14,000 yen and kept its buy rating. The shares are up 1.1% at 12,405 yen.
why it matters
For investors, the key question is the quality of earnings: steadier income from several franchises is typically valued by the market above dependence on one product. This is the analysts' view, not confirmed company results.
tags
instruments
sources
- Otsuka Holdings' Shift to Higher-Value Assets May Boost Margins — Market Talk, 13 November 2026 at 02:23 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗